Clinical trials: MCI Conversion to Dementia
MCI, MCI Conversion to Dementia
Neurocognitive Assessment Platform 4 Alzheimer
The aging population in Europe is leading to an increase in neurodegenerative diseases, such as Alzheimer's disease (AD), which is expected to affect 152 million people worldwide by 2050.
- Conditions
- MCI, MCI Conversion to Dementia, AMCI - Amnestic Mild Cognitive Impairment, Alzheimer Disease
- Trial name
- NAP4A2020 (NCT07272811)
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- IRCCS San Raffaele
Mild Cognitive Impairment, Dementia
A 3 Year Study to Evaluate the Safety and Efficacy of Low Dose Ladostigil in Patients With Mild Cognitive Impairment
The purpose of this study is to determine whether treatment with the investigational drug ladostigil will delay the onset of Alzheimer's disease(AD) in patients with Mild Cognitive Impairment (MCI).
- Trial name
- NCT01429623
- Testing
- ladostigil hemitartrate
- Where
- 12 sites in Austria, Germany and 1 more
- Volunteers
- 210 people
- Sponsor
- Avraham Pharmaceuticals Ltd
Alzheimer Disease, Cerebral Amyloid Angiopathy
Auburn University Research on Olive Oil for Alzheimer's Disease (AU-ROOAD)
Until now there is no medical treatment and/or intervention that can slow, stop or reverse the underlying neurodegenerative of Alzheimer's disease (AD).
- Trial name
- (AU-ROOAD) (NCT03824197)
- Testing
- EVOO, OO
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Auburn University
Mild Cognitive Impairment
A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting
This study will be conducted to evaluate the rate of Alzheimer's disease conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.
- Trial name
- CONCORDE (NCT03448445)
- Testing
- Usual care setting
- Where
- 16 sites in South Korea
- Volunteers
- 201 people
- Sponsor
- Eisai Korea Inc.
Alzheimer s Disease, MCI Conversion to Dementia
Development of a Home Test for Measuring Blood P-tau217 in Alzheimer's Disease Using the Tasso Lancet Device
This study compares p-tau217 concentrations in blood collected via the Tasso device versus standard venipuncture in subjects with and without Alzheimer's disease, including a subset with confirmed amyloid pathology.
- Conditions
- Alzheimer s Disease, MCI Conversion to Dementia, pTau217, Biomarkers
- Trial name
- NCT07701161
- Where
- 5 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Neurogen Biomarking LLC
Biomarkers, MCI Conversion to Dementia
Exploring the Predicting Biomarkers From Mild Cognitive Impairment to Dementia (EBMID)
Mild cognitive impairment (MCI) represents a transitional stage between healthy aging and dementia, and affects more than 15% of the population over the age of 60 in China.
- Trial name
- NCT05697588
- Where
- China
- Volunteers
- 900 people, healthy volunteers welcome
- Sponsor
- Cuibai Wei，Clinical Professor
Mild Cognitive Impairment
Long Term Prospective Study of Tai Chi Intervention to Prevent MCI From Conversion to Dementia
This study evaluates the effects of 3 years-Tai Chi exercise intervention on cognitive function in MCI patients and to clarify whether the intervention can prevent MCI from conversion to dementia.
- Trial name
- TIME (NCT05310890)
- Testing
- Tai chi training, Group activity
- Volunteers
- 206 people
- Sponsor
- Ruijin Hospital
Mild Cognitive Impairment
A Trial of Cilostazol in Patients With Mild Cognitive Impairment (COMCID)
Epidemiological, clinicopathological and animal studies show that vascular disease in various forms contributes to cognitive decline.
- Trial name
- NCT02491268
- Testing
- Cilostazol
- Where
- Japan
- Volunteers
- 166 people
- Sponsor
- National Cerebral and Cardiovascular Center, Japan
Mild Cognitive Impairment
Psychopathological Risk Factors Associated With Conversion From Mild Cognitive Impairment to Dementia
Background: Dementias (Alzheimer's disease and related syndromes), in their sporadic form, have multifactorial origin. Several risk factors (RF) are currently recognized like the cardiovascular RF, some genes of susceptibility…
- Trial name
- FPRMCI (NCT01436552)
- Where
- France
- Volunteers
- 392 people
- Sponsor
- Centre Hospitalier Esquirol
Behavioral and Psychological Symptoms of Dementia, Dementia
Validation and Reliability of the Turkish Version of the Montreal Cognitive Assessment-Basic (MoCA-B) in Individuals With Low Educational Level
This study aimed to evaluate the validity, reliability, and diagnostic accuracy of the Turkish version of MoCA-B in distinguishing healthy controls, mild cognitive impairment (MCI), and dementia patients within a low-education…
- Conditions
- Behavioral and Psychological Symptoms of Dementia, Dementia, Dementia (Diagnosis), Dementia Alzheimer Type
- Trial name
- MoCA-B Turkish (NCT07630688)
- Where
- Turkey (Türkiye)
- Volunteers
- 166 people, healthy volunteers welcome
- Sponsor
- Antalya Training and Research Hospital
Mild Cognitive Impairment, Alzheimer Disease
Predicting the Conversion From Mild Cognitive Impairment to Dementia
Mild cognitive impairment (MCI) is believed to be the early stage of dementia. The investigators assume that some psychological and imaging risks may predict the conversion.
- Conditions
- Mild Cognitive Impairment, Alzheimer Disease, Dementia, Vascular
- Trial name
- PCMCItoD (NCT01823666)
- Where
- China
- Volunteers
- 250 people
- Sponsor
- Dongzhimen Hospital, Beijing